Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3820392 | 1.00 | GSK3B (0.55) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL1129958 | 0.87 | GSK3B (0.70) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL1129666 | 0.87 | GSK3B (0.70) | GSK3BCYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL1130392 | 0.86 | GSK3B (0.69) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2405305 | 0.86 | GSK3B (0.56) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2405306 | 0.86 | GSK3B (0.56) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3824066 | 0.85 | GSK3B (0.57) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL3818044 | 0.85 | GSK3B (0.57) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2403980 | 0.84 | GSK3B (0.56) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2403164 | 0.84 | GSK3B (0.56) | GSK3BCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603910-B1 | SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES | SANOFI AVENTIS (FR) | 2009-08-26 | — | — | EP | claimed |
| US-7452897-B2 | Use of substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives for the treatment of neurodegenerative diseases | SANOFI-AVENTIS (FR) | 2008-11-18 | — | — | US | claimed |
| EP-1454908-B1 | Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives | SANOFI AVENTIS (FR) | 2008-02-27 | — | — | EP | claimed |
| US-20070167455-A1 | USE OF SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | claimed |
| US-7211581-B2 | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives | SANOFI-AVENTIS (FR) | 2007-05-01 | — | — | US | claimed |
| US-20060025417-A1 | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives | SANOFI-AVENTIS (FR) | 2006-02-02 | — | — | US | claimed |
| EP-1454908-A1 | Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives | SANOFI-SYNTHELABO (FR) | 2004-09-08 | — | — | EP | claimed |
| EP-1603910-B1 | SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES | SANOFI AVENTIS (FR) | 2009-08-26 | — | — | EP | disclosed |
| EP-2033963-A1 | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives | Sanofi-Aventis (FR) | 2009-03-11 | — | — | EP | disclosed |
| US-7452897-B2 | Use of substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives for the treatment of neurodegenerative diseases | SANOFI-AVENTIS (FR) | 2008-11-18 | — | — | US | disclosed |
| EP-1454908-B1 | Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives | SANOFI AVENTIS (FR) | 2008-02-27 | — | — | EP | disclosed |
| US-20070167455-A1 | USE OF SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
| US-7211581-B2 | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives | SANOFI-AVENTIS (FR) | 2007-05-01 | — | — | US | disclosed |
| US-20060025417-A1 | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives | SANOFI-AVENTIS (FR) | 2006-02-02 | — | — | US | disclosed |
| EP-1603910-A1 | SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004078759-A1 | SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | WO | disclosed |
| EP-1454908-A1 | Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives | SANOFI-SYNTHELABO (FR) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025417-A1 | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives | IDH3A, NAT1, IDH2 | GSK3B 3614/4885CYP1A2 79/4885CYP2D6 11/4885 |
| US-20070167455-A1 | USE OF SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PSEN2, PSEN1, GSK3A | GSK3B 4/4885CYP1A2 779/4885CYP2D6 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.